GWPH - GWファ―マシュ―ティカルズ (GW Pharmaceuticals Plc)


   Samantha Gleit – Behind Debt Structure In Today's Cannabis Industry  2021/03/23 17:25:10 Benzinga
Feuerstein Kulick LLP was a sponsor at the Benzinga Cannabis Capital Conference on February 25-26, 2021. The information contained in this article in no way represents investment advice or opinion on the part of Benzinga or its writers and is intended for informational purposes only. Navigating through the different complexities in the cannabis industry with limited liquidity sources and a state-by-state regulatory regime is time-consuming and can add an extra cost to a company’s structure. If a company doesn’t strategically plan ahead to address growth and capital needs, it can be detrimental in the increasingly competitive market. Thus, financial and legal planning is crucial in the evolving cannabis landscape, and having an experienced, reliable legal team can make or break a company. In recent months we’ve seen several high-profile transactions achieving scale through M&A activity. From names like Curaleaf Holdings Inc. (OTCQX: CURLF ), Heritage Cannabis (CSE: CANN) (OTCQX: HERTF ), Jazz Pharmaceuticals (NASDAQ: JAZZ ) GW Pharmaceuticals (NASDAQ: GWPH ), Cresco Labs (OTC: CRLBF ), Canopy Growth Corp. (NASDAQ: CGC ) and Indus Holding Inc. (OTCQX: INDXF ) acquiring Lowell Herb Co. among others, the market will keep gaining momentum.
   GW Pharmaceuticals plc (NASDAQ:GWPH) Director Cabot Brown Sells 4,020 Shares  2021/03/23 09:00:41 Watchlist News
GW Pharmaceuticals plc (NASDAQ:GWPH) Director Cabot Brown sold 4,020 shares of the business’s stock in a transaction dated Thursday, March 18th. The shares were sold at an average price of $17.95, for a total transaction of $72,159.00. Following the completion of the sale, the director now owns 7,200 shares in the company, valued at $129,240. […]
   Epilepsy Market Undertake Strapping Growth By 2027 With LivaNova PLC, GlaxoSmithKline PLC, Eisai Co. Ltd., Pfizer Inc., Medtronic PLC, GW Pharmaceuticals PLC, Novartis AG, Johnson & Johnson Services Inc., Abbott Laboratories, Becton Dickinson and Company  2021/03/22 09:06:26 OpenPR
Epilepsy research report provides deep insights into the Global Epilepsy market revenue, parent market trends, macro-economic indicators, and governing factors, along with market attractiveness per market segment. The report provides an overview of the growth rate of the Epilepsy during
   SHAREHOLDER ALERT: WeissLaw LLP Reminds EGOV, GWPH, PRSP and CMD Shareholders About Its Ongoing Investigations  2021/03/17 20:12:00 PR Newswire
NEW YORK, March 17, 2021 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: Joshua Rubin, Esq. WeissLaw LLP 1500 Broadway, 16th Floor…
   SHAREHOLDER ALERT: WeissLaw LLP Reminds SPWH, ENBL, EGOV, and GWPH Shareholders About Its Ongoing Investigations  2021/03/10 17:33:00 PR Newswire
NEW YORK, March 10, 2021 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: Joshua Rubin, Esq. WeissLaw LLP 1500 Broadway, 16th Floor…
   British tycoon dubbed 'Dr Pot' sells cannabis business for whopping £5.3billion  2021/02/04 09:22:43 Daily Star
Geoffrey Guy got the nickname after his drugs company GW Pharmaceuticals started using cannabis to develop medicines in the US - which has been snapped up by an Irish firm
   Dr Pot pots £66m: Cannabis medicine pioneer sells GW Pharmaceuticals for £5.3billion  2021/02/04 00:59:11 Daily Mail Online
Dr Geoffrey Guy has sold GW Pharmaceuticals, the cannabis company he founded in 1998, for £5.3bn. The company makes Sativex, the first cannabis-based medicine approved by any country.
   SHAREHOLDER ALERT: WeissLaw LLP Investigates GW Pharmaceuticals plc  2021/02/03 21:46:00 PR Newswire
NEW YORK, Feb. 3, 2021 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of GW Pharmaceuticals plc ("GWPH" or the "Company") (NASDAQ: GWPH) in connection with the proposed acquisition of the Company by…
   ‘Dr Pot’s’ £65m payday as cannabis pioneer bought by rival for £5.3bn  2021/02/03 21:19:00 Evening Standard
GW Pharmaceuticals, the Cambridge-based medicinal cannabis pioneer behind epilepsy treatment Epidolex, has been snapped up by rival healthcare group Jazz in a $7.2billion (£5.3billion) deal.
   Jazz Pharma to buy GW Pharmaceuticals in a $7.2 billion cash-and-stock deal  2021/02/03 20:29:00 Business Standard
GW Pharma's Epidiolex, the first marijuana-derived drug to be approved in the United States, generated sales of over $500 million for the U.K.-based company last year
   The Week In Cannabis: Stocks Spike By Double Digits On Earnings, Strong Sales, Financings  2021/01/16 14:25:13 Benzinga
Cannabis stocks widely outperformed the markets after a slew of financing deals and strong earnings reports. “The cannabis industry is off to a great start this year with New York state pushing hard for legalization," Green Market Report editor-in-chief Debra Borchardt said. "In addition to that several companies like GrowGeneration and GW Pharmaceuticals reported stellar earnings. Plus, Subversive Capital closed on the largest SPAC in the industry. Hopefully, the good news in 2021 will continue unlike the curveball thrown at us in 2020.” ETFs were all up by double digits. Over the last five trading days: The ETFMG Alternative Harvest ETF (NYSE: MJ ): gained almost 18% The AdvisorShares Pure Cannabis ETF (NYSE: YOLO ): was up almost 12% The Cannabis ETF (NYSE: THCX ): rose 18.4% The Amplify Seymour Cannabis ETF (NYSE: CNBS ): advanced 13.9s% The SPDR S&P 500 ETF Trust (NYSE: SPY ) was down 1.57% Benzinga Cannabis content is now available in Spanish on El Planteo . Sale Trends Cannabis sales in Michigan hit $984.6 million in 2020.
   GW Pharma expects fiscal 2020 sales to reach $526 million  2021/01/13 19:26:53 Marijuana Business Daily
United Kingdom-based GW Pharmaceuticals expects to report annual sales of approximately $526 million for the year ended Dec. 31, 2020, it said in a preview of its fourth quarter and full-year results. Fourth quarter net sales will be approximately $148 million, based on preliminary unaudited financial information, GW said in a news release this week. […] GW Pharma expects fiscal 2020 sales to reach $526 million is a post from: Marijuana Business Daily: Financial, Legal & Cannabusiness news for cannabis entrepreneurs
   Cannabis Companies Entered 2021 With A Bang  2021/01/13 15:37:22 Benzinga
The Democratic win that joined the wave of state legalization is encouraging for the cannabis market. Based on their most recent quarterly filing, Canopy Growth Corp (NASDAQ: CGC ), Cronos Group Inc (NASDAQ: CRON ), GW Pharmaceuticals PLC (NASDAQ: GWPH ), Aphria Inc (NASDAQ: APHA ) that announced it will merge with Tilray Inc (NASDAQ: TLRY ) in mid-December and Trulieve Cannabis Corp (OTC: TCNNF ), entered 2021 with the most cash on their balance sheets. But other stocks such as Curaleaf Holdings Inc (OTC: CURLF ), Cresco Labs Inc (OTC: CRLBF ), Planet 13 Holdings Inc (OTC: PLNHF ), Innovative Industrial Properties Inc (NYSE: IIPR ) and Green Thumb Industries Inc (OTC: GTBIF ) show a lot of potential as well, along with several powerful small caps. Being Cash-Rich Is Not Is As It Seems Aphria is yet to produce a net profit but it is in a great position to expand into the U.S. market as mass legalization continues. Another catalyst for growth is its announced $4 billion merger with Tilray.
   Global Medical Marijuana Market 2021: Covering Competitive Scenario And Dynamics By Canopy Growth Corporation, GW Pharmaceuticals plc, Emerald Health Therapeutics Inc., Tilray  2021/01/12 13:46:41 OpenPR
Medical marijuana market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market to account to USD 179,254.20 million by 2027 growing at a CAGR of 34.56% in the
   Merrill Lynch Stick to Their Buy Rating for GW Pharma By  2021/01/11 19:55:10
Merrill Lynch Stick to Their Buy Rating for GW Pharma